A DT I-NP O 0,1
limitation NN I-NP O 2,12
of IN I-PP O 13,15
the DT I-NP O 16,19
pharmacyte NN I-NP I-P 20,30
approach NN I-NP I-P 31,39
is VBZ I-VP O 40,42
the DT I-NP O 43,46
one-time JJ I-NP O 47,55
nature NN I-NP O 56,62
of IN I-PP O 63,65
the DT I-NP O 66,69
intervention: JJ I-NP O 70,82
ACT NNP I-NP I-M 84,87
T-cells NNP I-NP I-M 88,95
can MD I-VP O 96,99
only RB I-VP O 100,104
be VB I-VP O 105,107
loaded VBN I-VP O 108,114
once RB O O 115,119
with IN I-PP O 120,124
a DT I-NP O 125,126
cargo NN I-NP O 127,132
of IN I-PP O 133,135
adjuvant JJ I-NP I-M 136,144
drug NN I-NP I-M 145,149
prior RB O O 150,155
to TO I-VP O 156,158
transfer, VB I-VP O 159,167
and CC I-VP O 169,172
the DT I-NP O 173,176
duration NN I-NP O 177,185
of IN I-PP O 186,188
stimulation NN I-NP I-P 189,200
is VBZ I-VP O 201,203
inherently RB I-VP O 204,214
limited VBN I-VP O 215,222
by IN I-PP O 223,225
expansion NN I-NP I-P 226,235
of IN I-PP I-P 236,238
the DT I-NP I-P 239,242
cell NN I-NP I-P 243,247
population NN I-NP I-P 248,258
in IN I-PP I-P 259,261
vivo, JJ I-NP I-P 262,266
since IN I-PP O 268,273
cell-bound NN I-NP I-M 274,284
particles NNS I-NP I-M 285,294
are VBP I-VP O 295,298
diluted VBN I-VP O 299,306
with IN I-PP O 307,311
each DT I-NP O 312,316
cell NN I-NP I-M 317,321
division. NN I-NP I-P 322,330

We PRP I-NP O 332,334
hypothesized VBD I-VP O 335,347
that IN I-PP O 348,352
a DT I-NP O 353,354
strategy NN I-NP O 355,363
to TO I-VP O 364,366
target VB I-VP O 367,373
supporting VBG I-VP I-M 374,384
drugs NNS I-NP I-M 385,390
to TO I-VP O 391,393
T-cells NNS I-NP I-M 394,401
with IN I-PP O 402,406
nanoparticle JJ I-NP I-M 407,419
drug NN I-NP I-M 420,424
carriers NNS I-NP I-M 425,433
directly RB O O 434,442
in IN I-PP O 443,445
vivo NN I-NP O 446,450
would MD I-VP O 451,456
enable VB I-VP O 457,463
transferred JJ I-NP I-M 464,475
lymphocytes NNS I-NP I-M 476,487
to TO I-VP O 488,490
be VB I-VP O 491,493
repeatedly RB O O 494,504
stimulated VBN I-VP O 505,515
with IN I-PP O 516,520
supporting VBG I-VP I-M 521,531
adjuvant JJ I-NP I-M 532,540
drugs, NN I-NP I-M 541,546
and CC O O 548,551
thereby RB O O 552,559
provide VB I-VP O 560,567
continuous JJ I-NP O 568,578
supporting VBG I-NP O 579,589
signals NNS I-NP O 590,597
over IN I-PP O 598,602
the DT I-NP O 603,606
prolonged JJ I-NP O 607,616
durations NNS I-NP O 617,626
that WDT B-NP O 627,631
might MD I-VP O 632,637
be VB I-VP O 638,640
necessary JJ I-NP O 641,650
for IN I-PP O 651,654
elimination NN I-NP I-T 655,666
of IN I-PP I-T 667,669
large JJ I-NP I-T 670,675
tumor NN I-NP I-T 676,681
burdens. NN I-NP I-T 682,689

Such JJ I-NP O 691,695
“re-arming” NNS I-NP I-P 696,707
of IN I-PP I-P 708,710
T-cells NNP I-NP I-M 711,718
with IN I-PP I-P 719,723
supporting VBG I-VP I-M 724,734
drugs NNS I-NP I-M 735,740
could MD I-VP O 741,746
be VB I-VP O 747,749
achieved VBN I-VP O 750,758
by IN I-PP O 759,761
repeated JJ I-NP O 762,770
administration NN I-NP I-P 771,785
of IN I-PP I-P 786,788
targeted JJ I-NP I-P 789,797
particles, NN I-NP I-P 798,807
allowing VBG I-VP O 809,817
adoptively-transferred JJ I-NP I-M 818,840
T-cells NNS I-NP I-M 841,848
to TO I-VP O 849,851
be VB I-VP O 852,854
restimulated VBN I-VP O 855,867
multiple JJ I-NP O 868,876
times NNS I-NP O 877,882
directly RB O O 883,891
in IN I-PP O 892,894
vivo, NN I-NP O 895,899
while IN I-PP O 901,906
the DT I-NP O 907,910
use NN I-NP O 911,914
of IN I-PP O 915,917
internalizing VBG I-VP I-M 918,931
targeting VBG I-VP I-M 932,941
ligands NNS I-NP I-M 942,949
would MD I-VP O 950,955
minimize VB I-VP O 956,964
the DT I-NP O 965,968
likelihood NN I-NP O 969,979
of IN I-PP O 980,982
immune JJ I-NP O 983,989
responses NNS I-NP O 990,999
against IN I-PP O 1000,1007
the DT I-NP O 1008,1011
nanoparticle NN I-NP I-M 1012,1024
carrier. NN I-NP I-M 1025,1032

To TO I-VP O 1034,1036
our PRP$ I-NP O 1037,1040
knowledge, NNS I-NP O 1041,1050
only RB O O 1052,1056
two CD I-NP O 1057,1060
prior JJ I-NP O 1061,1066
studies NNS I-NP O 1067,1074
have VBP I-VP O 1075,1079
attempted VBN I-VP O 1080,1089
to TO I-VP O 1090,1092
target VB I-VP O 1093,1099
nanoparticles NNS I-NP I-M 1100,1113
to TO I-VP O 1114,1116
T-cells NNS I-NP I-M 1117,1124
in IN I-PP O 1125,1127
vivo NN I-NP O 1128,1132
[17,18]. NN I-NP O 1133,1140

In IN I-PP O 1142,1144
both DT I-NP O 1145,1149
of IN I-PP O 1150,1152
these DT I-NP O 1153,1158
studies, NNS I-NP O 1159,1166
particles NNS I-NP O 1168,1177
were VBD I-VP O 1178,1182
targeted VBN I-VP O 1183,1191
to TO I-VP O 1192,1194
T-cells NNP I-NP I-M 1195,1202
via IN I-PP O 1203,1206
peptide-MHC JJ I-NP I-M 1207,1218
ligands NNS I-NP I-M 1219,1226
that WDT B-NP O 1227,1231
bind VBP I-VP O 1232,1236
to TO I-VP O 1237,1239
specific JJ I-NP O 1240,1248
T-cell NNP I-NP I-M 1249,1255
receptors. NN I-NP I-M 1256,1265

However, NNP I-NP O 1267,1274
peptide-MHC-functionalized JJ I-NP I-M 1276,1302
nanoparticles NNS I-NP I-M 1303,1316
have VBP I-VP O 1317,1321
recently RB I-VP O 1322,1330
been VBN I-VP O 1331,1335
shown VBN I-VP O 1336,1341
to TO I-VP O 1342,1344
deliver VB I-VP O 1345,1352
an DT I-NP O 1353,1355
anergizing/tolerizing VBG I-NP O 1356,1377
signal NN I-NP O 1378,1384
to TO I-VP O 1385,1387
T-cells NNP I-NP I-M 1388,1395
[18,19] NNP I-NP O 1396,1403
— NNP I-NP O 1404,1405
which WDT B-NP O 1406,1411
is VBZ I-VP O 1412,1414
ideal JJ I-NP O 1415,1420
for IN I-PP O 1421,1424
treating VBG I-VP I-T 1425,1433
graft NN I-NP I-T 1434,1439
rejection NN I-NP I-T 1440,1449
or CC O I-T 1450,1452
autoimmunity, NN I-NP I-T 1453,1465
but CC O O 1467,1470
runs VBZ I-VP O 1471,1475
counter NN I-NP O 1476,1483
to TO I-VP O 1484,1486
the DT I-NP O 1487,1490
goals NNS I-NP O 1491,1496
of IN I-PP O 1497,1499
cancer NN I-NP I-T 1500,1506
immunotherapy. NN I-NP I-T 1507,1520

